virus covid-19

IMV to progress clinical development of Covid-19 vaccine

Reading now: 215
www.pharmaceutical-technology.com

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates IMV has initiated plans to progress the clinical development of a Covid-19 vaccine candidate, to determine the clinical safety and immunogenicity.

Based on the company’s DPX delivery technology, the vaccine candidate DPX-COVID-19 comprises peptides that target epitopes from the novel coronavirus strain.

The peptide-based approach, along with the DPX platform, speeds up the development and production of a vaccine. IMV plans to advance its vaccine candidate into Phase I clinical trial.

IMV CEO Frederic Ors said: “Across our many clinical studies, we have observed DPX technology to elicit a robust immune response with a sustained effect, including in

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA